Workflow
澄星股份: 上海荣正企业咨询服务(集团)股份有限公司关于江苏澄星磷化工股份有限公司2025年限制性股票激励计划调整及首次授予相关事项之独立财务顾问报告

Core Viewpoint - Jiangsu Chengxing Phosphate Chemical Co., Ltd. has initiated a stock incentive plan for 2025, which includes adjustments and the first grant of restricted stocks to incentivize key personnel and enhance company performance [1][7][12]. Summary by Sections Independent Financial Advisor Report - The independent financial advisor confirms that the stock incentive plan has been approved and complies with relevant laws and regulations [5][12]. - The plan involves granting restricted stocks to directors, senior management, core personnel, and high-potential employees [8][12]. Approval Process - The necessary approvals for the stock incentive plan have been obtained, including resolutions from the board of directors and the supervisory board [6][7]. - The company has publicly disclosed the list of incentive recipients and received no objections during the public notice period [6][7]. Adjustments to the Incentive Plan - The initial list of 86 recipients has been adjusted to 79 due to 7 individuals voluntarily waiving their rights to the restricted stocks [8][9]. - The total number of restricted stocks granted has been reduced from 16 million shares to 14.24 million shares [8][9]. Granting Conditions and Schedule - The incentive plan's effective period lasts up to 66 months, with a vesting schedule that includes a 12-month, 24-month, and 36-month lock-up period for the granted stocks [9][10]. - The conditions for lifting the restrictions on the stocks include meeting specific performance criteria and compliance with legal regulations [8][10]. Financial Impact - The independent financial advisor emphasizes the need for accurate accounting of the stock incentive plan's impact on the company's financial status and operating results, in accordance with accounting standards [12]. Conclusion - The independent financial advisor concludes that the adjustments and initial grants of the stock incentive plan have met all necessary legal and regulatory requirements, and the company will proceed with the required disclosures and follow-up procedures [12].